Cargando…

Genetic profiling of CLL: a ‘TP53 addict' perspective

Detalles Bibliográficos
Autores principales:	Lodé, L, Cymbalista, F, Soussi, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	News and Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816188/ https://www.ncbi.nlm.nih.gov/pubmed/26775696 http://dx.doi.org/10.1038/cddis.2015.415

Ejemplares similares

Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
por: Catherwood, Mark A., et al.
Publicado: (2022)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle
por: Watier, Hervé
Publicado: (2018)

Exploiting tumour addiction with a serine and glycine-free diet
por: Amelio, Ivano, et al.
Publicado: (2017)

Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases
por: Soussi, Thierry, et al.
Publicado: (2022)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

A tale of two alleles: TP53 and transformation in MPNs
por: Brierley, Charlotte, et al.
Publicado: (2022)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers?
por: Tuveson, David, et al.
Publicado: (2015)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries
por: Carbonnier, Vincent, et al.
Publicado: (2020)

PXR interaction with p53: a meeting of two masters
por: Robbins, D, et al.
Publicado: (2016)

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)

p53-guided response to nucleostemin loss in normal versus cancer cells
por: Tsai, R Y L
Publicado: (2015)

Reactivation of p53 via MDM2 inhibition
por: Kim, E S, et al.
Publicado: (2015)

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
por: Kwok, Marwan, et al.
Publicado: (2021)

Novel function of cytoplasmic p53 at the interface between mitochondria and the endoplasmic reticulum
por: Kroemer, G, et al.
Publicado: (2015)

A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53
por: Glazer, Robert I.
Publicado: (2010)

Spontaneous and inherited TP53 genetic alterations
por: Levine, Arnold J.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The role of 53BP1 protein in homology-directed DNA repair: things get a bit complicated
por: Malewicz, Michal
Publicado: (2016)

Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds
por: Kalos, Michael
Publicado: (2016)

NF-Y joins E2Fs, p53 and other stress transcription factors at the apoptosis table
por: Gatta, R, et al.
Publicado: (2011)

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

Vaccination against COVID-19: a challenge in CLL
por: Eichhorst, Barbara
Publicado: (2021)

Common genetic variants in the TP53 pathway and their impact on cancer
por: Barnoud, Thibaut, et al.
Publicado: (2019)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vu53v2ta11ast032pr45dhu05r